Amgen, AbbVie Agree to Settlement Regarding Biosimilar Adalimumab

October 3, 2017

Biosimilars Team

Amgen has reached a global settlement with AbbVie to resolve all pending litigation regarding Amgevita/Amjevita, a biosimilar to AbbVie’s Humira (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of the biosimilars worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation. Amgen expects to launch Amgevita in Europe on October 16, 2018, and Amjevita (adalimumab-atto) in the United States on January 31, 2023.

Specific financial terms of the agreement were not disclosed.